Lung Cancer: the first male cancer death
Time:2009-11-06 10:18 Author:admin Hits:
Among the cancer, to the number of lung cancer incidence and cause of death in the highest.
The incidence of lung cancer in China continued to increase in recent years, the annual incidence rate has reached 35 hundred thousandths, 70% of patients had developed to late diagnosis, no cure. Lung Cancer has become China's first male cancer death, female cancer, the second cause of death.
To this end, the State Food and Drug Administration approved the introduction of a applies to all non-small cell lung cancer patients a new targeted therapy Tarceva (Erlotinib), an official at China's listed. Well-known lung cancer expert, Professional Committee of Chinese Anti-Cancer Association, lung cancer, chairman of Professor Wu Yilong, said: "to Tarceva as the representative of molecular targeted therapy is the world's revolutionary breakthrough in the field of lung cancer, lung cancer represents the development trend of the future." The drug, respectively, in November 2004 and September 2005 in the United States and Europe, through the examination and approval, after the failure of chemotherapy for non-small cell lung cancer b / c-line treatment in the global market more than 75 countries have ratified.
Lung cancer is the world's most common form of cancer, one of the 1.2 million new cases each year. Non-small cell lung cancer, which accounts for about 80%. Of lung cancer has a very high mortality rate, every 30 seconds there is one person died of lung cancer. The past, mainly with advanced lung cancer with chemotherapy, treatment is very limited, and patients with more severe side effects.
The incidence of lung cancer in China continued to increase in recent years, the annual incidence rate has reached 35 hundred thousandths, 70% of patients had developed to late diagnosis, no cure. Lung Cancer has become China's first male cancer death, female cancer, the second cause of death.
To this end, the State Food and Drug Administration approved the introduction of a applies to all non-small cell lung cancer patients a new targeted therapy Tarceva (Erlotinib), an official at China's listed. Well-known lung cancer expert, Professional Committee of Chinese Anti-Cancer Association, lung cancer, chairman of Professor Wu Yilong, said: "to Tarceva as the representative of molecular targeted therapy is the world's revolutionary breakthrough in the field of lung cancer, lung cancer represents the development trend of the future." The drug, respectively, in November 2004 and September 2005 in the United States and Europe, through the examination and approval, after the failure of chemotherapy for non-small cell lung cancer b / c-line treatment in the global market more than 75 countries have ratified.
Lung cancer is the world's most common form of cancer, one of the 1.2 million new cases each year. Non-small cell lung cancer, which accounts for about 80%. Of lung cancer has a very high mortality rate, every 30 seconds there is one person died of lung cancer. The past, mainly with advanced lung cancer with chemotherapy, treatment is very limited, and patients with more severe side effects.
